Evidence map›Paper›PMID 36276234›Full record

ArticleCEUR workshop proceedings2019

Comparing the representation of medicinal products in RxNorm and SNOMED CT - Consequences on interoperability.

Jean Noel Nikiema, Olivier Bodenreider

Abstract read
In one paragraph

Article in CEUR workshop proceedings, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jean Noel NikiemaBordeaux Population Health Research Center, ERIAS, Univ. Bordeaux, Inserm UMR 1219, F-33000, Bordeaux, France.
Olivier BodenreiderU.S. National Library of Medicine National Institutes of Health Bethesda, Maryland, USA.

Funding

Medical Ontology ResearchZIALM010017 · NLM · NATIONAL LIBRARY OF MEDICINE · PI BODENREIDER, OLIVIER · 2021 to 2023
$6.0M
Intramural NIH HHS ZIA LM010017
6 · The paper itself

Abstract

Objectives: To compare the representation of medicinal products in RxNorm and SNOMED CT and assess the consequences on interoperability. Methods: To compare the two models, we manually establish equivalences between the types and definitional features of medicinal products entities in RxNorm and SNOMED CT. We highlight their similarities and differences. Results: Both models share major definitional features including ingredient (or substance), strength and dose form. SNOMED CT is more rigorous and better aligned with international standards. In contrast, RxNorm contains implicit knowledge, simplifications and ambiguities, but its model is simpler. Conclusions: Since their models are largely compatible, medicinal products from RxNorm and SNOMED CT are expected to be interoperable. However, specific aspects of the alignment between the two models require particular attention.

Indexed as

medicinal productsRxNormSNOMED CT

Identifiers

PMID36276234
PMCPMC9584356

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.